A longitudinal safety and efficacy study of abatacept evaluating the effect of age on risk-benefit ratio in patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry

Trial Profile

A longitudinal safety and efficacy study of abatacept evaluating the effect of age on risk-benefit ratio in patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Mar 2016

At a glance

  • Drugs Abatacept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms ORA registry
  • Most Recent Events

    • 11 Feb 2016 New trial record
    • 27 Jan 2016 Results published in the Rheumatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top